Dementia Congress Market Analysis and Reports | singapore Conference Series

Market Analysis - Dementia Congress 2018

Theme: Exploring the Challenges and Excellence in Dementia Research

Dementia congress 2018 welcomes attendees, presenters, and exhibitors from all over the world to Singapore. We are delighted to invite you all to attend and register for the 12th World Congress on Advances and Innovations in Dementia which is going to be held during September 17-18, 2018 in Singapore.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Dementia congress 2018, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Dementia congress 2018 organizing committee look forward to meeting you in Singapore.

For more details please visit - http://dementiacongress.neurologyconference.com

Why in Singapore?

One in 10 people aged 60 and above in Singapore have dementia, according to a new nationwide study. Findings on how common the illness is and its impact on caregivers emerged on Wednesday from the $4.4 million Well-being of the Singapore Elderly (WiSE) study, which interviewed almost 5,000 seniors and their family members. Its growing prevalence is a concern, according to Institute of Mental Health experts who collaborated with other international investigators for the three-year research. Most countries have a prevalence rate of 5 to 7 per cent, though researchers from IMH said countries that used the same diagnostic tool as the one in the WiSE study, such as urban China and India, registered an 8 per cent prevalence. A World Health Organisation survey on ageing carried out here 20 years ago found that only 3 per cent were diagnosed with dementia. Professor Chong Siow Ann, vice-chairman of the IMHs medical board (research), who led the WiSE study, said: The concern is how we can use the study to assess if we have adequate resources to meet the challenges we have right now and those that are going to be emerging. IMH experts attribute the rise in prevalence rate to a rapidly ageing population and increasing prevalence of stroke, obesity, diabetes and hypertension that are risk factors for dementia. Patients with dementia, a progressive brain disorder, may suffer from memory loss and have difficulty expressing themselves. In 2012, about 28,000 people in Singapore aged 60 and older had dementia. The number is expected to soar to 80,000 by 2030. The study also found that age, stroke as well as education and employment were associated factors. Caregivers of those with dementia also report significantly higher levels of distress and psychological problems compared to other caregivers.

According to the latest Well-being of the Singapore Elderly (WiSE) study conducted by the Institute of Mental Health (IMH), one in 10 people aged 60 and above in Singapore has dementia. The results of this study, funded by the Ministry of Health and the Singapore Millennium Foundation, which involved about 5,000 elderly and their caregivers over a period of three years, are cause for concern. In 2012, a total of 28,000 Singaporeans above the age of 60 had dementia. This number is expected to rise to 80,000 by 2030, as Singapores population continues to age.

 

 

Importance and Scope:

The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.

Someone in the world develops dementia every 3 seconds. There were an estimated 46.8 million people worldwide living with dementia in 2015 and this number is believed to be close to 50 million people in 2017. This number will almost double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Much of the increase will be in developing countries. Already 58% of people with dementia live in low and middle income countries, but by 2050 this will rise to 68%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific neighbours.

Major Neuroscience Societies and Associations in Singapore:

Singapore NeuroScience Association

National Neuroscience Institute

Neurology Asia

Asian-Pacific Society for Neurochemistry

Clinical Neuroscience Society Singapore

Child Neurology Society


Major Dementia and alzheimers Societies and Associations around Globe:

Alzheimers Australia

Hilarescere Foundation in Italy

Alzheimer Society of Bangladesh

Alzheimer Support Group

Alzheimers Association

Southern Clinical Neurological Society

American Academy of Neurology

ESNR European Society of Neuroradiology

European Neurological Societies

Alzheimer Austria

Foundation Alzheimer Aruba (FAA)

Alzheimers disease Chinese

Spanish Society of Neurology

Alzheimers Society

Major Neurological Associations in Italy

British brain tumor association


Top Neuroscience Universities in Singapore:

National Neuroscience Institute

Cognitive Neuroscience Lab

National University of Singapore

National Institute of Education

Nanyang Technological University

Singapore Neurology and Sleep Center

Duke–NUS Medical School

Devathasan Neurology & Medical Pte Ltd

National University Health System

Singapore Management University


Top Neuroscience Universities in Globe:

Dalhousie University

University of Nottingham

Leiden University

Cardiff University

Temple University USA

University of Toronto

University Oklahoma

University Sheffield

University of Bristol

University California

Florida International University

University of Amsterdam

University of Edinburgh

Karolinska Institute

University of Milan

University of Gothenburg


Hospital Associated with Dementia :

SBCC Baby & Child Clinic (Neurology Centre)

Tang Neurology & Medical Clinic

Vision 2 Engineering Pte. Ltd

Raffles Neuroscience Centre

P N Chong Neurology Clinic

Mount Elizabeth Hospital

Tan Chai Beng

Dr Adrian Tan Keng Yew

Ho Neurology Pte Ltd

Gleneagles Hospital

National Neuroscience Institute

National University Hospital


Companies Associated with Dementia in Singapore

iNova Pharmaceuticals (Singapore) Pte. Limited

Johnson & Johnson

Medicell Pharmaceutical (S) Pte. Ltd

West Pharmaceutical

GSK Quality Road

Merck Pte Ltd

GSK Jurong

Poli Medical Company Pte Ltd


Top Dementia Companies:

Brainomix

Polyneuron Pharmaceuticals AG Corp.

reHaptix GmbH

Biogen Idec

KB Medical

Intento SA

OncoVision

AcelRx Pharmaceuticals, Inc.

Trevena

AcelRx Pharmaceuticals, Inc.

Mintlabs

Mylan

Actavis

Bayer

Lundbeck

Novartis


Glance at market of dementia:-

The total estimated worldwide cost of dementia is US$818 billion in 2015, which represents 1.09% of global GDP. By 2018, the global cost of dementia will rise above a US$ trillion.

This figure includes costs attributed to informal care (unpaid care provided by family and others), direct costs of social care (provided by community care professionals, and in residential home settings) and the direct costs of medical care (the costs of treating dementia and other conditions in primary and secondary care).

Direct medical care costs account for roughly 20% of global dementia costs, while direct social sector costs and informal care costs each account for roughly 40%. The relative contribution of informal care is greatest in the African regions and lowest in North America, Western Europe and some South American regions, while the reverse is true for social sector costs.

This means that if global dementia care were a country, it would be the 18th largest economy in the world. The annual costs exceed the market values of companies such as Apple (US $742 billion) and Google (US $368 billion). More information is available in our World Alzheimer Report 2015.

 

 

Some products manufactured by the industry related Neuroscience Research:-

  •  NeuroScience ImmuWell.
  • NeuroScience AdreCor.
  • NeuroScience Calm CP.
  • Kavinace .
  • Purified anti-β-Dystroglycan Antibody.
  • Alexa Fluor® 594 anti-Neurofilament H (NF-H), Phosphorylated Antibody.
  • Mouse & Rat  Spinal Cord Matrices.
  • Surgical & Dissection Tools. 

Target Audience:

Neurologists and Directors, Physicians, Neuroscientists, Specialists, researchers, health care professionals, Professors, Lecturers and Students from Academia in the study of Dementia.

Products manufactured by the industries:

Three drugs are available to treat symptoms in people with Mild to moderate Alzheimers disease

Aricept produced by Pfizer Canada Inc.,

Exelon produced by Novartis Pharma Canada Inc.

Reminy produced by Janssen Ortho Inc.

Two drugs for Moderate to advanced Alzheimers disease

Ebixa

Aricept

References:

http://www.alzheimers.org.uk/dementiauk

https://en.wikipedia.org/wiki/Alzheimers_Research_UK

http://www.alzheimersresearchuk.org/

http://www.alz.org/uk/dementia-alzheimers-uk.asp

http://www.alzheimersresearchuk.org/about-dementia/facts-stats/

http://www.alz.org/research/funding/alzheimers_our_commitment.asp

https://www.ucl.ac.uk/dementia

http://www.city.ac.uk/courses/cpd/evidence-based-dementia-care

http://www.kcl.ac.uk/ioppn/depts/oldage/research/bdr.aspx

 

About Conference

Dementia Congress 2018, 12th World Congress on Advances and Innovations in Dementia, which is held during September 17-18, 2018 at Singapore. The main theme of our conference is Exploring the Challenges and Excellence in Dementia Research which covers wide range of critically important sessions. Its a platform to bring all the neuroscientists together to share their experiences its the amalgam of scientific research as well as innovative ideas.

Neurological disorders are diseases of the brain, spine and the nerves that connect them. There is ample evidence that pinpoints neurological disorders as one of the greatest threats to public health. There are more than 600 diseases of the nervous system, such as Alzheimer disease, brain tumours, epilepsy, Parkinsons disease, and stroke, dementia as well as less familiar ones such as frontotemporal dementia.

In the present day scenario a wide population of mankind are plagued by mental and neurological illnesses, with almost 165 million people or 38percent of the population suffering each year from a brain disorder. With only about a third of cases receiving the therapy or medication needed, mental illnesses cause a huge economic and social burden, it found the cost burden of these and neurological disorders amounted to about 386 billion euros ($555 billion) a year. An estimated 6.8 million people die every year as a result of neurological disorders.

Neurological disorders public health challenges describes and discusses the increasing global public health importance of common neurological disorders such as dementia, epilepsy, headache disorders, multiple sclerosis, neuroinfections, neurological disorders associated with malnutrition, pain associated with neurological disorders, stroke and traumatic brain injuries.

National Alliance provided fund of $650 million to fuel the research on mental illness. NARSAD Young Investigator Grant provides $30,000 per year on research in Neural and behaviour disorders such as dementia, schizophrenia, mood disorders, anxiety disorders, or child and adolescent mental illnesses. Brain tumor research receives less than 1% (0.7%) of national cancer research spending in the UK.

 In order to accelerate the research in the field of Neuroscience Conference Series organizes different conference series worldwide.

About Organization

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference
  • Unique Opportunity! Online visibility to the Speakers and Experts

Highlights:

Brain diseases

Schizophrenia

Neurodegenerative Diseases

Autism

Dementia

Diagnosis of dementia

Alzheimers disease

Dementia Management

Anxiety & Depression

Animal Models in Dementia

Parkinsons diseases

Drug Development in Dementia

Recent Advancement in Treatments of Dement

Clinical Trials & Case Reports in Dementia

Who should attend?

  • Neuroscientist
  • neuroanatomist
  • Neurobiologist
  • Neurochemist
  • Neurological Surgeon
  • Neurologist
  • Neuropathologist
  • Neuropharmacologist
  • Neurophysiologist
  • Neuropsychologist
  • Neuroradiologist
  • Psychobiologist
  • Biological Psychologist
  • Psychiatrist
  • Neuroscience Nurse
  • Psychophysicist
  • Professors
  • Students
  • Neuro drug Manufacturers

Benefits of attending:

  • Networking Opportunities, Grow Your Professional Network
  • Build Your Knowledge Base
  • Expand Your Resources
  • Meet Experts & Influencers Face to Face
  • Learning In a New Space
  • Break Out of Your Comfort Zone
  • New Tips & Tactics
  • Greater Focus
  • The Serendipity of the Random Workshop

Who should sponsor/exhibit:

  • Pharmaceuticals
  • Drug Manufacturers
  • Hospitals
  • Educational Institutes
  • Research Centers